R

Royalty Pharma plc
D

RPRX

33.420
USD
0.07
(0.21%)
Market Closed
Volume
191,779
EPS
3
Div Yield
2.54
P/E
17
Market Cap
14,481,718,325
OverviewSignalsIdeasNews
Related Instruments
    A
    AKBA
    -0.10500
    (-5.53%)
    1.79500 USD
    C
    CRBP
    -0.09000
    (-1.09%)
    8.20000 USD
    E
    ETON
    0.080
    (0.55%)
    14.500 USD
    G
    GLYC
    -0.00930
    (-3.06%)
    0.29490 USD
    K
    KPTI
    -0.00940
    (-1.55%)
    0.59840 USD
    V
    VKTX
    2.480
    (7.85%)
    34.090 USD
    V
    VNDA
    -0.08500
    (-1.89%)
    4.41500 USD
    X
    XNCR
    -0.030
    (-0.19%)
    15.740 USD
    More
News

Title: Royalty Pharma plc

Sector: Healthcare
Industry: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.